







# A Situational Analysis of Childhood Cancer Care Services in India 2022

ICMR - National Centre for Disease Informatics and Research







Impacting NCD Public Health Actions and Policies
Collaborate Innovate Inspire

# A Situational Analysis of Childhood Cancer Care Services in India





This report was prepared by the Indian Council of Medical Research - National Centre for Disease Informatics and Research, through technical and financial support from World Health Organization (India Office)

Published by:

ICMR- National Centre for Disease Informatics and Research, Bengaluru 562110

director-ncdir@icmr.gov.in September, 2022

### Cite as:

ICMR- National Centre for Disease Informatics and Research. Situational analysis of childhood cancer care services in India. Bengaluru: ICMR- NCDIR; 2022





	Contents	Page number
	Message from MOHFW, Government of India	iv
	Message from DG ICMR	v
	Message from WHO	vi
	Message from Director, ICMR-NCDIR	vii
	Executive summary	1
	Key findings	2
Α.	Definitions	4
В.	Abbreviations	7
C.	Figures	8
D.	Tables	10
1.	Introduction	11
2.	Methodology	15
3.	Results	18
Section A	Status of childhood cancer care services at tertiary and secondary level hospitals	
3.1	Participation rates	18
3.2	Type of hospitals	18
3.3	Average number of childhood cancer cases treated every year	19
3.4	Referral linkages	20
3.5	Cancer care departments and care coordination	22
3.6	Availability of diagnostic facilities	27
3.7	Cancer-specific treatment procedures	28
3.8	Human resources	30
3.9	Physical infrastructure	32
3.10	Medications for treating childhood cancer	33
3.11	Treatment guidelines	37
3.12	Financing of treatment	38
3.13	Pediatric oncology training programmes	39
3.14	Childhood cancer-related activities on awareness and early diagnosis	40
3.15	Medical record system at tertiary hospitals	40
3.16	Research Activities among the tertiary hospitals	41





Section B	Barriers and facilitators in the delivery of childhood cancer services in India	
3.17	Challenges faced in diagnosing and treating childhood cancers	42
3.18	Challenges faced by patients and caregivers regarding treatment	44
3.19	Impact of COVID-19 pandemic on the delivery of childhood cancer care services	
4.	Suggestions on how the components of childhood cancer care could be improved and strengthened (all stakeholders)	50
5.	Summary	53
6.	The way forward	56
	Annexure 1. List of ICMR investigators and experts	59
	Annexure 2. List of nodal hospitals	61
	Annexure 3. List of participating hospitals	64
	Annexure 4. List of state nodal officers	80
	Annexure 5. List of civil society organizations	81
	Annexure 6. Additional tables and figures	82
	Annexure 7. Snapshot of the dashboard	119
	Annexure 8. Statistical terms	120





**Dr. Sudarsan Mandal, MD**Deputy Director General
Directorate General of Health Services





Tel.: 011-23061803 E-mail: mandals.aiihph@gov.in sudarsannrs.1962@gmail.com

भारत सरकार
Government of India
स्वास्थ्य एवं परिवार कल्याण मंत्रालय
Ministry of Health & Family Welfare
निर्माण भवन, नई दिल्ली—110011
Nirman Bhawan, New Delhi-110011

### Message

Childhood cancers contribute to a reasonable quantum of morbidity and mortality among children and adolescents. The current childhood health programmes focus on infectious diseases and nutritional problems, while the cancer control programmes aim to prevent and control cancer in adults. Hence, childhood cancers have not received the due attention, resulting in delays in diagnosis and treatment with consequent poor disease outcomes since children with cancer often present with advanced-stage disease. Lack of sturdy referral systems is one of the reasons for late-stage presentations and delayed diagnosis.

The 'Situational Analysis of Childhood Cancer Care Services in India' conducted by the WHO and ICMR-NCDIR, MoHFW aimed to describe the status and challenges in delivering quality childhood cancer services. The survey has attempted to provide a nationwide presentation by including tertiary and secondary level hospitals in 27 states and 3 union territories and concerned state health officials and non-profit organisations engaged with childhood cancer care.

The findings in this report could be used to accelerate the preparedness and capacity of the health system to address childhood cancer in India. Multisectoral efforts to enhance awareness, treatment-seeking and treatment adherence, combined with robust policy implementation, would be of immense help in improving survival in patients of childhood cancer.

(Dr Sudarsan Mandal)

कमरा नं. 343 बी, ए—विंग, निर्माण भवन, नई दिल्ली—110011 Room No. 343 B, A-Wing, Nirman Bhavan, New Delhi-110011







### प्रोफेसर (डा.) बलराम भार्गव, पदम श्री

एमडी, डीएम, एफआरसीपी (जी.), एफआरसीपी (ई.), एफएसीसी, एफएचए, एफएएमएस, एफएनएएस, एफएएससी, एफ.एन.ए., डी.एस.सी.

सचिव, भारत सरकार स्वास्थ्य अनुसंधान विभाग स्वास्थ्य एवं परिवार कल्याण मंत्रालय एवं महानिदेशक, आई सी एम आर

### Prof. (Dr.) Balram Bhargava, Padma Shri

MD, DM, FRCP (Glasg.), FRCP (Edin.), FACC, FAHA, FAMS, FNASc, FASc, FNA, DSc

### Secretary to the Government of India

Department of Health Research Ministry of Health & Family Welfare & Director-General, ICMR



### भारतीय आयुर्विज्ञान अनुसंधान परिषद

स्वास्थ्य अनुसंघान विभाग स्वास्थ्य एवं परिवार कल्याण मंत्रालय भारत सरकार वी. रामलिंगस्वामी भवन, अंसारी नगर नई दिल्ली - 110 029

### **Indian Council of Medical Research**

Department of Health Research Ministry of Health & Family Welfare Government of India V. Ramalingaswami Bhawan, Ansari Nagar New Delhi - 110 029

### Message

The landscape of childhood cancer is witnessing a changing trend, and is a cause of major concern. The recent findings from the National Cancer Registry Programme reportshave shown that the proportion of childhood cancers (0-14 years) relative to all cancers was 4%. Data from the Population Based Cancer Registries indicate variations in childhood cancer incidence in different registry covered areas throughout the country. Compared to higher-income countries, the survival rate of childhood cancers is less in India and is mainly attributed to delays in care-seeking, delayed diagnosis and low treatment adherence.

There is absence of a childhood cancer policy and program in the country. To start the process study entitled 'Situational analysis of childhood cancer care services in India' was conducted by ICMR-NCDIR, with support from the World Health Organization, for a comprehensive description of the status of childhood care services available at tertiary and secondary level care hospitals across the country. The study attempted to describe the obstacles in delivering optimal care and factors that could be conducive to strengthening childhood cancer care services in India.

I hope this report will be a valuable resource for stakeholders concerned with childhood cancer care services in the country and encourage appropriate research. This would pave the way for formulating suitable policy and programmatic interventions for addressing childhood cancer care.

Balrane Brogan

(Balram Bhargava)







### Message

Cancer is a one of the leading causes of death for children and adolescents in India. More than 80% of children with cancer can be treated and cured. However, late diagnosis, inaccessible therapy, lack of skilled workforce, inadequate diagnostics facilities, treatment inertia and avoidable relapse result in lower survival rates.

The cause for a vast majority of childhood cancers is unknown, which makes prevention challenging. Early diagnosis followed by effective, evidence-based therapy and customised supportive care is the most effective strategy to reduce the cancer burden in children and improve outcomes. Paediatric palliative care, while a core component of comprehensive care, is often neglected.

The World Health Organization (WHO) Global Initiative for Childhood Cancer is part of the response to the World Health Assembly resolution on cancer prevention and control through an integrated approach (WHA70.12). The initiative aims to increase political commitment for childhood cancer control; develop standards and tools to guide interventions for early diagnosis, treatment, palliative care, and survivorship care; improve access to essential medicine and technologies; and protect families from financial hardship and social isolation as a result of cancer care.

The South-East Asia Regional Office has set up SEAR Childhood Cancer Network to support member countries to improve knowledge on the latest evidence-based interventions and build capacity for a strong childhood cancer response.

WHO India, in collaboration with ICMR National Centre for Disease Informatics and Research, conducted a situation analysis of childhood cancer services at the national and subnational levels to assess the availability of childhood cancer care services, treatment practices, care pathways and to document facility preparedness for the provision of childhood cancer care services. Key informant interviews with state programme managers, cancer institutions (public and private), and civil society organisations across country have helped in framing barriers and facilitators in childhood cancer service delivery to optimise treatment and care.

We are confident that the findings from the assessment will help narrow critical gaps in information. The high-quality data will inform national policies, strategies and interventions to improve survival and the quality of life of paediatric cancer patients across the country.

Dr Roderico H. Ofrin WHO Representative to India

532, A - Wing, Nirman Bhawan, Maulana Azad Road, New Delhi 110 011 | Tel. 91-11- 66564800 | Fax. 91-11-23062450, 26162996 www.searo.who.int/india









डॉ प्रशान्त माथुर डो सी एव. डी एन बी, पी एव. डी., एम एन ए एम एस चित्रेशक

**Dr Prashant Mathur** DCH, DNB, Ph.D., MNAMS Director E-mail: director-ncdir@icmr.gov.in आई सी एम आर - राष्ट्रीय रोग सूचना विज्ञान एवं अनुसंधान केंद्र स्वास्थ्य अनुसंधान विभाग, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, भारत सरकार

ICMR - National Centre for Disease Informatics and Research
Department of Health Research, Ministry of Health
and Family Welfare, Government of India

### Foreword

Cancers are an increasing burden on individuals and society. The latest ICMR-NCDIR National Cancer Registry Report 2021 showed that childhood cancers (0-14 years) accounted for 4% of all cancers recorded between 2012-2019. These cancers occur at younger ages and have no established known preventive steps to be taken. Thus the mainstay of handling them is efficient treatment and care. In the absence of any policy or program specifically addressing childhood cancers in India, the necessary impetus is lacking. To begin the process, with the support and collaboration of the World Health Organization (WHO India and Regional Offices), a national level survey on comprehensive situational analysis of childhood cancer care services in India was undertaken to describe the landscape of such services and identify gaps, which would help to improve the quality of care and survival outcomes.

The report "A situational analysis of childhood cancer care services in India" describes the rationale, methodology and results of this study that was conducted in 137 tertiary and 101 secondary level hospitals (public, private and not-for profit) in 26 States and 4 Union Territories. Data was captured through software based tools on aspects related to diagnosis, referral, treatment, availability of equipment's/drugs/devices, human resources, teaching and training programs, challenges in managing childhood cancers and policy interventions needed. The concerned hospital key informant, state NPCDCS nodal officers and civil society organizations were also assessed for their views on these topics and suggestions on scaling and strengthening of childhood cancer care services in India.

It is hoped that this report will help in formulating relevant discussions around childhood cancer care services in the country and development of a policy to address its needs.

Prashant Mathur

निर्मल भवन, आई सी एम आर काँप्लेक्स, पूजनहल्ली रोड, कन्नमंगला पोस्ट, बेंगलुरु - 562 110. कर्नाटक (भारत)

Nirmal Bhawan-ICMR Complex, Poojanahalli Road, Kannamangala Post, Bengaluru - 562 110. Karnataka (India)



NATIONAL NATIONAL REGISTRY PROGRAMME India

Tel: +91 080 22176400 Fax: 080 30723643 Email Id: ncdir@ncdirindia.org https://www.ncdirindia.org

# **Executive summary**

### **Background**

Childhood cancer constitutes the invisible portion of the "cancer iceberg" to a large extent. The proportion of childhood cancers in India contributing to the global statistics is significant. In this context, the narrative of childhood cancer care services gains importance. Delayed diagnosis and treatment initiation are the commonly proposed reasons for poor survival outcomes in childhood cancer. Assessing the present situation of childhood cancer care services is essential to suggest reforms and shape programmatic and policy interventions. The survey aimed to assess the status of childhood cancer care services in India regarding availability, facility preparedness and capacity, treatment-related practices, and perceived barriers and facilitators in diagnosing and treating childhood cancers.

### Methodology

The ICMR- National Centre for Disease Informatics and Research (NCDIR), the central coordinating agency, provided technical support, including overall supervision, study tools and an online portal, survey implementation, and data management and statistical analysis. The situational analysis was conducted using a cross-sectional survey design. The participants included 137 tertiary level hospitals, 92 secondary level hospitals, 16 state nodal officers for NPCDCS and nine civil society organizations/non-governmental organizations (CSOs/NGOs) in 26 states and four union territories (UT). A nodal hospital was identified in each state/ UT and required to further identify a representative network of three to five cancer-treating hospitals (tertiary level) and two to three district/sub-district hospitals (secondary level), depending upon the geographical size of the region. The questionnaire was administered through an online portal. Descriptive statistics were used to analyse and present the final survey results.





### **Key findings**

- Over two-thirds of the government tertiary hospitals had referral linkages with lower-tier non-childhood cancer-treating facilities; however, such links were seen in less than half (45.7%) of the private tertiary hospitals.
- Childhood cancer care services were provided at over one-third (39.1%) of the Secondary level hospitals, which was higher in private (56.5%) than public (32.8%) hospitals.
- A dedicated paediatric oncology department was available in less than half of the public and private tertiary hospitals.
- The majority of the tertiary level hospitals had supportive care facilities, including blood banks, nutritional rehabilitation, physiotherapy, psychological counselling and parental education. However, facilities for hospice care were available in less than half of the hospitals.
- Over three quarters (76.6%) of the public tertiary hospitals adopted a multidisciplinary team approach for childhood cancer treatment, compared to 35% of the private hospitals.
- More than 90% of the tertiary hospitals had facilities for histopathology; however, a lower
  proportion of public tertiary hospitals had facilities for immunohistochemistry,
  flowcytometric immunophenotyping, cytogenetics, tumour markers and fluorescence in
  situ hybridization (FISH), which about half of the public tertiary hospitals provided
  referral services for those investigations.
- Over 80% of the tertiary hospitals had facilities for CT scans, MRI and ultrasonograms; however, the availability of bone scans and PET scans was lower, especially in public sector hospitals.
- Less than a quarter (20.8%) of the public hospitals had facilities for Haemopoietic Stem Cell Transplantation (HSCT) compared to half of the private hospitals (54.3%).
- At public tertiary hospitals, less than half of the hospitals had a pediatric oncologist (48%), pediatric oncosurgeon (14.2%), pediatric intensivist (38.9%), medical oncologist (46.7%) and palliative care physician (37.6%).
- Nurses specialized in pediatric cancer, and palliative care was available in less than 50% of the public and private tertiary hospitals.
- Among palliative care medications, methadone and morphine oral liquid stocks were available in less than 30% of the public, private, and tertiary hospitals. A larger proportion





of targeted therapies were not available at the public tertiary hospitals compared to private hospitals.

- A higher proportion of private secondary level hospitals had cancer-treating medications in stock among the secondary hospitals.
- The most commonly adopted financing mechanism comprised the Ayushman Bharat Scheme at public tertiary level hospitals and secondary level public hospitals and ESI/State specific schemes at private tertiary hospitals.
- Only about a third of the tertiary hospitals had active pediatric oncology clinical research programs at Hospital or pediatric oncology unit/ward
- For public tertiary and secondary level hospitals, the major challenges faced included shortage of human resources, lack of beds, shortage of equipment and lack of physical space for extending facilities. Shortage of human resources was an essential concern for private tertiary and secondary hospitals.
- The most frequent challenge patients and their caregivers faced regarding treatment was treatment denial and treatment abandonment, for which financial constraints were the most commonly cited reason.
- The delivery of childhood cancer care services at over half of the tertiary hospitals was impacted by the COVID pandemic resulting in a decreased diagnosis of new pediatric cases in a majority of the hospitals and increased rates of treatment abandonment.

The situational analysis of childhood cancer care services in India reiterates a skewing in the availability of childhood cancer care services at the tertiary level of health care. Most childhood cancers are associated with non-modifiable risk factors. The key to a better prognosis and favourable outcomes is early and accurate diagnosis and timely initiation of effective treatment. The need of the hour is to formulate a childhood cancer policy that will enable timely diagnosis, treatment, supportive care and follow-up through well-defined care pathways.





### A. Definitions

**Availability of diagnostic and treatment services:** Physical presence of the laboratory services, radiologic/nuclear investigation and specific procedures and treatment interventions for cancer. For the available services, service utilization was measured through tracer items that included average time to avail services, referral to other centres, and the means opted for making the referral.

Capacity building: Training and technical assistance that builds resources enabling communities to deliver evidence-based interventions

Cancer care facilities and coordination: Ability of the health facility to offer either diagnosis or treatment for childhood cancers in the hospital. The capacity to provide this was measured through tracer items that included availability of departments and average waiting time for getting an appointment, supportive care facilities, social support, multidisciplinary team approach, treatment decision and patient follow-up.

**Continuing medical education**: A continuing education process to learn about new and developing areas of a field, upgrade and maintain professional competence.

**Chemotherapy:** Type of cancer-treating modality that uses one or more anti-cancer medicines to halt the growth of cancer cells, either by killing or stopping the cells from dividing. Chemotherapy may be given orally or parentally, depending on the type and stage of cancer. It may be given alone or with other treatments, such as surgery, radiation therapy, or biologic therapy.

**Financing of treatment:** mode adopted for paying for childhood hood cancer care. This included government financing, state-specific financing, individual private insurance and employment-based group private insurance.

A formal agreement for patient referral: A signed acknowledgement between two health care facilities in which they agree to attend to a referred patient and coordinate patient care between the two facilities.

**Health insurance** is an agreement between the insured and the insurer that is effective when an adverse health event occurs. The insurer will reimburse the compensation either to the insured person or the health service provider.





**Information, Education and Communication** (IEC) is a "public health approach that aims to change or reinforce health-related behaviours in a defined target audience, concerning a specific problem using varied communication methods".

**A medical oncologist** is the "primary health care provider for an individual diagnosed with cancer. The doctor specialises in diagnosing and treating cancer".

The medical record system refers to the "availability of digital versions of the patient paper charts at the hospitals".

**Multi-speciality Hospital** offers "tertiary care and specialized care in multiple specialities through an expert team of medical specialists and allied health personnel".

**Nutritional Rehabilitation Centers** are care units where "severely acute malnourished (SAM) children below five years are admitted with their mothers/caregivers for treatment, stabilization and rehabilitation".

**Physical infrastructure, equipment and medicines:** Physical infrastructure relevant for managing childhood cancer services at the Hospital included the following services as broad categories; beds, systemic therapy and supportive care.

The medications were broadly classified as a medicine for palliative/supportive care, medication for other symptoms common in palliative care and supportive drugs. Each medication was checked for availability, stock-outs per year, and procurement.

**Palliative care** is a specialized area of medical care that aims to relieve patients from pain and other cancer-related symptoms.

**Service availability:** Physical presence of health delivery services, including health infrastructure, essential health personnel and features of service utilization.

**Secondary level Hospital:** Refers to hospitals at the second tier of the health system, which attend to patients referred from health centres at the primary level.

**Treatment guidelines** encompassed the recommended guidelines adopted at each hospital for leukaemia, lymphoma, brain tumours, neuroblastoma, Wilms tumour and bone cancer. It also included written protocols for administering chemotherapy, managing febrile neutropenia, and central venous access devices.





**Tumour board meeting** includes a group of doctors and other health care providers with different specialities that meet regularly at the hospital to discuss cancer cases and share knowledge.

**Telemedicine:** Health care services delivery using technologies for information and communication employed by health care providers in places where distance is critical. It helps to exchange meaningful information for the prevention, diagnosis and treatment of disease and injuries, enables research and evaluation, and helps in the continuing education of health care providers, all in the interests of promoting the health of individuals and communities."

**Tertiary level hospital:** Includes hospitals at the third tier of the health system. Specialized treatment and care are provided, usually based on a referral from health facilities at the primary and secondary levels.

**Treatment abandonment:** Failure to complete treatment when the disease can be effectively controlled or missing therapy for a defined period affects disease prognosis.

**Treatment denial:** Non-acceptance or refusal to undergo treatment that the attending health care provider advises.





# **B.** Abbreviations

AAR	age-adjusted rate	
AARpm	age-adjusted rate per million	
CBC	complete blood count	
CGHS	Central Government Health Scheme	
CNS	central nervous system	
CSO	civil society organization	
CT	computed tomography	
ESI	Employees' State Insurance	
FISH	fluorescence in situ hybridization	
FNB	fellowship of the national board	
HBCR	hospital-based cancer registry	
HIC	high-income countries	
HLA	human leukocyte antigen	
HSCT	haemopoietic stem cell transplantation	
IAP	indian academy of pediatrics	
IMCI	integrated management of childhood illness	
IEC	information education communication	
LIC	low-income countries	
MIBG	iodine-123 meta-iodobenzylguanidine	
MRI	magnetic resonance imaging	
NCD	noncommunicable Disease	
NGO	non-governmental organization	
NPCDCS	National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke	
OOP	out-of-pocket	
PBCR	Population Based Cancer Registry	
PET CT	positron emission tomography and computed tomography	
РНО	pediatric hemato-oncology	
PICU	paediatric intensive care unit	
PM-JAY	Ayushman Bharat Pradhan Mantri Jan Arogya Yojana	
RBSK	Rashtriya Bal Swasthya Karyakram	
RDBMS	relational database management systems	
RT PCR	real-time polymerase chain reaction	
SARA	service availability and readiness assessment	
SIOP	societe internationale d'oncologie pediatrique	
WHO	World Health Organization	





# **Figures**

1	Representative network of participating hospitals
2	Data collection from participating hospitals
3	Average number of new cases of childhood cancers treated per year (2018-2020) at tertiary hospitals
4	Average number of childhood cancer cases treated per year (average over the last three years) at secondary hospitals
5	Percentage of tertiary level hospitals with referral linkages with lower tier health facilities
6	Means of obtaining referral of patients from lower tier health facilities
7	Referral linkages with cancer treating (tertiary) facilities
8	Means of referring patients to tertiary level cancer treating centres
9	Percentage of tertiary hospitals that followed a multidisciplinary team approach
10	Modes of implementing multidisciplinary team approach in managing childhood cancers- tertiary hospitals
11	Primary treatment decision-maker for a patient with childhood cancer at a tertiary hospital
12	Mechanism for follow-up of patients- tertiary hospitals
13	Availability of childhood cancer treating facilities at secondary hospitals
14	Availability of departments for childhood cancer treatment at secondary hospitals
15	Availability of supportive care facilities at secondary hospitals
16	Availability of radiologic and nuclear medicine services at tertiary hospitals
17	Availability of diagnostic services at Secondary hospitals
18	Availability of physical infrastructure relevant for managing childhood cancer services at the tertiary Hospitals
19	Availability of drugs at tertiary hospitals
20	Procurement of medications when not available at tertiary hospitals
21	Cost of medications at tertiary hospitals
22	Availability of medications for treating childhood cancer at public hospitals
23	Availability of medications for treating childhood cancer at private hospitals
24	Challenges in diagnosing and treating childhood cancers at tertiary hospitals
25	Challenges in diagnosing and treating childhood cancers at secondary hospitals
26	Challenges faced by patients and caregivers regarding treatment at tertiary hospitals
27	Challenges faced by patients and caregivers regarding treatment at secondary hospitals
28	Reasons for treatment denial as reported by secondary hospitals
29	Challenges in diagnosing childhood cancers as reported by SNOs and CSOs
30	Significant barriers in the treatment of childhood cancers- reported by SNOs and NGOs/CSOs
31	Impact of COVID 19 pandemic on the delivery of childhood cancer care services at tertiary hospitals
32	Impact of COVID 19 pandemic on the delivery of childhood cancer care services at secondary hospitals





Average waiting time to get an appointment according to departments at public tertiary hospitals  Average waiting time to get an appointment according to departments at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Average waiting time to avail of an appointment at public secondary hospitals  Average waiting time to avail of an appointment at NGOs/charitable hospitals  Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at private secondary hospitals  Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Costing of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineo	33	Proportion of secondary level facilities where social worker accompanies the referred
hospitals  Average waiting time to get an appointment according to departments at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at public tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Average waiting time to avail of an appointment at public secondary hospitals  Average waiting time for avail of an appointment at NGOs/charitable hospitals  Average waiting time for radiologic and nuclear medicine services at tertiary hospitals  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospitals  Means for seeking consultation from specialists not available in the tertiary hospitals  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Costing of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of antineoplastic drugs in pivate te		1 1
tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at public tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Average waiting time to avail of an appointment at public secondary hospitals  Average waiting time to avail of an appointment at public secondary hospitals  Average waiting time to avail of an appointment at NGOs/charitable hospitals  Average waiting time for radiologic and nuclear medicine services at tertiary hospitals  Average waiting time for radiologic and nuclear medicine services that are not available at the tertiary hospital  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at private secondary hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Availability of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Availability of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineo	34	
available at the hospital at public tertiary hospitals Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals Average waiting time to avail of an appointment at public secondary hospitals Average waiting time to avail of an appointment at public secondary hospitals Average waiting time for radiologic and nuclear medicine services at tertiary hospitals Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital and average waiting time for diagnostic services at private secondary hospitals Average waiting time for diagnostic services at NGO/charitable hospitals Average waiting time to avail of specified treatment procedures at a public tertiary hospital Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospitals Means for seeking consultation from paramedical specialists not available in the tertiary hospitals Costing of drugs used in palliative care in public tertiary hospitals Costing of drugs used in palliative care in private tertiary hospitals Costing of drugs used in palliative care in private tertiary hospitals Availability of drugs used in palliative care in private tertiary hospitals Costing of drugs used in targeted therapies in tertiary hospitals Costing of antineoplastic drugs in public tertiary hospitals Co	35	
available at the hospital at private tertiary hospitals  Availability and mode of referral services for supportive care services that are not available at the hospital at private tertiary hospitals  Average waiting time to avail of an appointment at public secondary hospitals  Average waiting time to avail of an appointment at private secondary hospitals  Average waiting time to avail of an appointment at NGOs/charitable hospitals  Average waiting time for radiologic and nuclear medicine services at tertiary hospitals  Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at private secondary hospitals  Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospitals  Means for seeking consultation from specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic dr	36	
available at the hospital at private tertiary hospitals  Average waiting time to avail of an appointment at public secondary hospitals  Average waiting time to avail of an appointment at private secondary hospitals  Average waiting time to avail of an appointment at NGOs/charitable hospitals  Average waiting time for radiologic and nuclear medicine services at tertiary hospitals  Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at private secondary hospitals  Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospital  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Costing of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals	37	*
40 Average waiting time to avail of an appointment at private secondary hospitals 41 Average waiting time to avail of an appointment at NGOs/charitable hospitals 42 Average waiting time for radiologic and nuclear medicine services at tertiary hospitals 43 Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital 44 Average waiting time for diagnostic services at public secondary hospitals 45 Average waiting time for diagnostic services at private secondary hospitals 46 Average waiting time for diagnostic services at NGO/charitable hospitals 47 Average waiting time to avail of specified treatment procedures at a public tertiary hospital 48 Average waiting time to avail of specified treatment procedures at a private tertiary hospital 49 Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital 50 Means for seeking consultation from specialists not available in the tertiary hospital 51 Means for seeking consultation from paramedical specialists not available in the tertiary hospitals 52 Availability of drugs used in palliative care in public tertiary hospitals 53 Costing of drugs used in palliative care in private tertiary hospitals 54 Availability of drugs used in palliative care in private tertiary hospitals 55 Costing of drugs used in palliative care in NGO/charitable tertiary hospitals 56 Availability of drugs used in palliative care in in NGO/charitable tertiary hospitals 57 Costing of drugs used in palliative care in in tertiary hospitals 58 Availability of drugs used in targeted therapies in tertiary hospitals 59 Costing of drugs used in targeted therapies in tertiary hospitals 60 Availability of antineoplastic drugs in public tertiary hospitals 61 Costing of antineoplastic drugs in public tertiary hospitals 62 Availability of antineoplastic drugs in private tertiary hospitals 63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in private tertiar	38	*
40 Average waiting time to avail of an appointment at private secondary hospitals 41 Average waiting time to avail of an appointment at NGOs/charitable hospitals 42 Average waiting time for radiologic and nuclear medicine services at tertiary hospitals 43 Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital 44 Average waiting time for diagnostic services at public secondary hospitals 45 Average waiting time for diagnostic services at private secondary hospitals 46 Average waiting time for diagnostic services at NGO/charitable hospitals 47 Average waiting time to avail of specified treatment procedures at a public tertiary hospital 48 Average waiting time to avail of specified treatment procedures at a private tertiary hospital 49 Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital 50 Means for seeking consultation from specialists not available in the tertiary hospital 51 Means for seeking consultation from paramedical specialists not available in the tertiary hospitals 52 Availability of drugs used in palliative care in public tertiary hospitals 53 Costing of drugs used in palliative care in private tertiary hospitals 54 Availability of drugs used in palliative care in private tertiary hospitals 55 Costing of drugs used in palliative care in NGO/charitable tertiary hospitals 56 Availability of drugs used in palliative care in in NGO/charitable tertiary hospitals 57 Costing of drugs used in palliative care in in tertiary hospitals 58 Availability of drugs used in targeted therapies in tertiary hospitals 59 Costing of drugs used in targeted therapies in tertiary hospitals 60 Availability of antineoplastic drugs in public tertiary hospitals 61 Costing of antineoplastic drugs in public tertiary hospitals 62 Availability of antineoplastic drugs in private tertiary hospitals 63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in private tertiar	39	Average waiting time to avail of an appointment at public secondary hospitals
Average waiting time to avail of an appointment at NGOs/charitable hospitals  Average waiting time for radiologic and nuclear medicine services at tertiary hospitals  Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at private secondary hospitals  Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospital  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Availability of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals	40	
Average waiting time for radiologic and nuclear medicine services at tertiary hospitals Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at private secondary hospitals  Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospitals  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Availability of drugs used in palliative care in NGO/charitable tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of antineoplastic drugs in public tertiary hospitals  Availability of antineoplastic drugs in public tertiary hospitals  Availability of antineoplastic drugs in public tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals		
Availability and mode of referral services for radiologic and nuclear services that are not available at the tertiary hospital  Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at private secondary hospitals  Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospitals  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Costing of drugs used in palliative care in public tertiary hospitals  Availability of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Availability of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals		
Average waiting time for diagnostic services at public secondary hospitals  Average waiting time for diagnostic services at private secondary hospitals  Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospital  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals	42	
45 Average waiting time for diagnostic services at private secondary hospitals 46 Average waiting time for diagnostic services at NGO/charitable hospitals 47 Average waiting time to avail of specified treatment procedures at a public tertiary hospital 48 Average waiting time to avail of specified treatment procedures at a private tertiary hospital 49 Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital 50 Means for seeking consultation from specialists not available in the tertiary hospital 51 Means for seeking consultation from paramedical specialists not available in the tertiary hospitals 52 Availability of drugs used in palliative care in public tertiary hospitals 53 Costing of drugs used in palliative care in private tertiary hospitals 54 Availability of drugs used in palliative care in private tertiary hospitals 55 Costing of drugs used in palliative care in NGO/charitable tertiary hospitals 56 Availability of drugs used in palliative care in NGO/charitable tertiary hospitals 57 Costing of drugs used in palliative care in NGO/charitable tertiary hospitals 58 Availability of drugs used in targeted therapies in tertiary hospitals 59 Costing of drugs used in targeted therapies in tertiary hospitals 60 Availability of antineoplastic drugs in public tertiary hospitals 61 Costing of antineoplastic drugs in public tertiary hospitals 62 Availability of antineoplastic drugs in private tertiary hospitals 63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in private tertiary hospitals	43	not available at the tertiary hospital
Average waiting time for diagnostic services at NGO/charitable hospitals  Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospital  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Availability of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals	44	Average waiting time for diagnostic services at public secondary hospitals
Average waiting time to avail of specified treatment procedures at a public tertiary hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospitals  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Costing of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals	45	Average waiting time for diagnostic services at private secondary hospitals
hospital  Average waiting time to avail of specified treatment procedures at a private tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospitals  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Costing of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	46	Average waiting time for diagnostic services at NGO/charitable hospitals
hospital  Average waiting time to avail of specified treatment procedures at NGO/charitable tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospital  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals	47	
tertiary hospital  Means for seeking consultation from specialists not available in the tertiary hospital  Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Availability of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals	48	
Means for seeking consultation from paramedical specialists not available in the tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in public tertiary hospitals  Availability of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals	49	
tertiary hospitals  Availability of drugs used in palliative care in public tertiary hospitals  Costing of drugs used in palliative care in public tertiary hospitals  Availability of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	50	Means for seeking consultation from specialists not available in the tertiary hospital
Costing of drugs used in palliative care in public tertiary hospitals  Availability of drugs used in palliative care in private tertiary hospitals  Costing of drugs used in palliative care in private tertiary hospitals  Availability of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals	51	
Availability of drugs used in palliative care in private tertiary hospitals Costing of drugs used in palliative care in private tertiary hospitals Availability of drugs used in palliative care in NGO/charitable tertiary hospitals Costing of drugs used in palliative care in NGO/charitable tertiary hospitals Availability of drugs used in targeted therapies in tertiary hospitals Costing of drugs used in targeted therapies in tertiary hospitals Costing of drugs used in targeted therapies in tertiary hospitals Availability of antineoplastic drugs in public tertiary hospitals Costing of antineoplastic drugs in private tertiary hospitals Availability of antineoplastic drugs in private tertiary hospitals Costing of antineoplastic drugs in private tertiary hospitals Availability of antineoplastic drugs in private tertiary hospitals Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	52	Availability of drugs used in palliative care in public tertiary hospitals
Costing of drugs used in palliative care in private tertiary hospitals  Availability of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	53	Costing of drugs used in palliative care in public tertiary hospitals
Availability of drugs used in palliative care in NGO/charitable tertiary hospitals  Costing of drugs used in palliative care in NGO/charitable tertiary hospitals  Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	54	Availability of drugs used in palliative care in private tertiary hospitals
57 Costing of drugs used in palliative care in NGO/charitable tertiary hospitals 58 Availability of drugs used in targeted therapies in tertiary hospitals 59 Costing of drugs used in targeted therapies in tertiary hospitals 60 Availability of antineoplastic drugs in public tertiary hospitals 61 Costing of antineoplastic drugs in public tertiary hospitals 62 Availability of antineoplastic drugs in private tertiary hospitals 63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	55	Costing of drugs used in palliative care in private tertiary hospitals
Availability of drugs used in targeted therapies in tertiary hospitals  Costing of drugs used in targeted therapies in tertiary hospitals  Availability of antineoplastic drugs in public tertiary hospitals  Costing of antineoplastic drugs in public tertiary hospitals  Availability of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Costing of antineoplastic drugs in private tertiary hospitals  Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	56	Availability of drugs used in palliative care in NGO/charitable tertiary hospitals
59 Costing of drugs used in targeted therapies in tertiary hospitals 60 Availability of antineoplastic drugs in public tertiary hospitals 61 Costing of antineoplastic drugs in public tertiary hospitals 62 Availability of antineoplastic drugs in private tertiary hospitals 63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	57	Costing of drugs used in palliative care in NGO/charitable tertiary hospitals
60 Availability of antineoplastic drugs in public tertiary hospitals 61 Costing of antineoplastic drugs in public tertiary hospitals 62 Availability of antineoplastic drugs in private tertiary hospitals 63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	58	Availability of drugs used in targeted therapies in tertiary hospitals
61 Costing of antineoplastic drugs in public tertiary hospitals 62 Availability of antineoplastic drugs in private tertiary hospitals 63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	59	Costing of drugs used in targeted therapies in tertiary hospitals
62 Availability of antineoplastic drugs in private tertiary hospitals 63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	60	Availability of antineoplastic drugs in public tertiary hospitals
63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	61	Costing of antineoplastic drugs in public tertiary hospitals
63 Costing of antineoplastic drugs in private tertiary hospitals 64 Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	62	
64 Availability of antineoplastic drugs in NGO/charitable tertiary hospitals	63	
	64	
	65	Costing of antineoplastic drugs in NGO/charitable tertiary hospitals





66	Reasons for treatment denial as reported by tertiary hospitals	
67	Reasons for treatment abandonment as reported by tertiary hospitals	
68	Reasons for treatment denial as reported by secondary hospitals	
69	Reasons for treatment abandonment as reported by secondary hospitals	

# **Tables**

1	Major source of financial support
2	Referral linkages with primary non-cancer treating facilities and mechanism of obtaining referred cases
3	Availability of childhood cancer treatment-related departments according to governance
4	Availability of supportive care facilities
5	Availability of laboratory services at tertiary hospitals
6	Availability of Specified procedures and treatment interventions- tertiary hospitals
7	Availability of written protocols at tertiary hospitals
8	Availability of human resources for childhood cancer care
9	Percentage of tertiary hospitals using treatment guidelines for the management of specific cancers
10	Financing of treatment
11	Pediatric oncology training programmes at tertiary hospitals
12	Childhood cancer-related activities on awareness and early diagnosis
13	Medical record system at tertiary hospitals
14	Research Activities among the tertiary hospitals
15	Suggestions on how the following components of childhood cancer care could be improved and strengthened
16	Availability of childhood cancer treatment-related departments by type of hospital
17	Availability of departments for childhood cancer treatment at secondary hospitals
18	Average waiting time for lab services at public tertiary hospitals
19	Average waiting time for lab services at private tertiary hospitals
20	Average waiting time for lab services at NGO/charitable tertiary hospitals
21	Availability and mode of referral services for laboratory services that are not available at the public tertiary hospital
22	Availability and mode of referral services for laboratory services that are not available at the private tertiary hospital
23	Availability and mode of referral services for laboratory services that are not available at NGO/charitable hospital
24	Delivery of childhood cancer care services at tertiary hospitals impacted by the COVID-19 pandemic